Cryoport Expands Its Global Reach with New Facility in Paris

Cryoport Expands Its Global Footprint with a New Facility in Paris

In a significant move to enhance its global presence, Cryoport, Inc. has unveiled its latest state-of-the-art facility in Louvres, just outside Paris, France. This new location serves as the latest addition to the company's Global Supply Chain Center (GSCC) network, significantly bolstering its capabilities in temperature-controlled supply chain solutions for the life sciences sector.

Strategic Location and Purpose-Built Facility

The new facility is strategically situated near Charles de Gaulle Airport, which is crucial for ensuring quick access to global markets. With an impressive footprint of 55,000 square feet, it is designed to meet the growing demand for temperature-sensitive logistics, especially in the advanced therapies domain. This center will enable Cryoport to provide comprehensive supply chain services under one roof, catering to various needs including biostorage, biologics, and future cryopreservation services.

Enhancing Support for Biopharma

The Paris GSCC is already operational and immediately offers tailored logistics support for biopharma entities. These include critical sectors like cell and gene therapies, biologics, animal health, and reproductive medicine. By providing integrated capabilities, the new facility aims to support both clinical and commercial programs, ensuring secure and compliant handling of temperature-sensitive commodities, which is vital for the efficacy of such therapies.

Jerrell Shelton, CEO of Cryoport, expressed his enthusiasm regarding this development, stating, "Our new facility in Louvres significantly strengthens Cryoport Systems' Global Supply Chain Center Network and gives us improved ability to serve our clients in European and global markets."

The company plans to progressively enhance the offerings at the Paris location. Within the coming months, it will introduce additional services such as BioServices, QP drug management, and Importer of Record (IOR) services, further solidifying its role in the life sciences supply chain.

24/7 Global Dispatch Capabilities

The facility also features 24-hour worldwide dispatch capabilities, ensuring that orders are processed and dispatched swiftly from the moment they are received. Utilizing Cryoport's proprietary shipping systems, the Paris GSCC will adhere to the same rigorous quality standards that characterize the entire Cryoport Systems network. This commitment to quality is crucial in facilitating the safe delivery of life-saving therapies.

Local Support and Economic Impact

The establishment of the Paris facility has been supported by a grant from the Île-de-France region, aimed at promoting economic growth within the area. An official grand opening ceremony is planned for November 20, 2025, which will gather local dignitaries, influential figures in the advanced therapies field, and market leaders.

Looking Forward

Cryoport, Inc., which is publicly traded on NASDAQ under the symbol CYRX, has consistently demonstrated its dedication to advancing temperature-controlled solutions in the life sciences. With this latest expansion, the company is well-positioned to address the complexities and challenges faced in the biopharmaceutical industry today. As stated by Shelton, the company is committed to "Enabling the Future of Medicine™," and this new facility in Paris is a significant step towards achieving that vision.

The introduction of the Paris Global Supply Chain Center marks an exciting chapter for Cryoport and the broader landscape of life sciences logistics, enhancing service capabilities and ensuring that temperature-sensitive therapies can reach patients safely and efficiently.